key: cord-0693657-ivwv602j authors: Fallah Vastani, Zahra; Ahmadi, Alireza; Abounoori, Mahdi; Rouhi Ardeshiri, Motahareh; Masoumi, Elham; Ahmadi, Iraj; Davodian, Abdollah; Kaffashian, Mohammadreza; Kenarkoohi, Azra; Falahi, Shahab; Mami, Sanaz; Mami, Sajad title: Interleukin‐29 profiles in COVID‐19 patients: Survival is associated with IL‐29 levels date: 2022-03-09 journal: Health Sci Rep DOI: 10.1002/hsr2.544 sha: a938545b1dc0eb0646e350448ea33e9dcf9f3ac7 doc_id: 693657 cord_uid: ivwv602j nan The 2019-novel coronavirus is the main reason for disaster in the recent century. 1 The innate immune system is the first line of antiviral defense. The host response and clearance of viral infections significantly rely on type I interferon (T1IFN) expression. It is guessed that SARS-CoV-2, similar to other coronaviruses, compromises the early defense against the virus because of delayed-T1IFN production and neutralizing T1IFN signaling through inhibition of STAT family transcription factor phosphorylation. Suppression of these innate immune mechanisms in infected cells permits coronaviruses without an impressive antiviral response to be proliferated. Also, an early burst of T1IFN leads to conservation against viral infections. 2 In this case, it has been demonstrated that the interferons type I and III are the essential components in defense against viruses. Shreds of evidence indicate that SARS-CoV-2 is sensitive to pretreatment with IFN-I/III in vitro. As a viral pathogenic mechanism, CoVs are using different tools for inhibition of induction and signaling of IFN-I. 3 Interleukin-29 (IL-29) (interferon-λ1) is a newly discovered member of type III interferon. 4 It is mostly produced by maturing dendritic cells and macrophages and involved in many immunological responses and indicates antiviral activity similar to T1IFNs. 5 Pegylated form of IFN-λ1 decreased the disease severity and transmission of SARS-CoV-2 in preclinical investigations on different animal models. 6 Due to limited research attending the role of IL-29 in COVID-19, it remains undecided whether IL-29 can affect the prognosis of COVID-19 or not. So, in the current study, we aimed to investigate whether IL-29 has a protective role in patients with COVID-19, and decreased levels of this cytokine could predict the severe condition in this disease or not. All dataset around physical and radiological detections, laboratory tests, and demographic characteristics were rolled up from medical records. Also, the time from disease onset to hospitalization, duration of hospitalization, and hospital discharge time were determined for improved patients. The body temperature of all individuals was measured using an infrared thermometer. Venous blood samples were collected from very severe COVID-19 cases, who later died during the current investigation, improved patients. The blood samples were collected in tubes for the serum extraction and allowed to be clotted for 10-15 min at room temperature. Then tubes were centrifuged (at 2000-3000 revolutions per minute) for 10 min, then immediately aliquoted, and stored at −20°C until measurement by the enzyme-linked immunosorbent assay (ELISA). Serum levels of IL-29 from these two study groups were determined by human IL-29 96-well plates ELISA Kit (ZellBio GmbH). After preparing reagents, samples, and the standards, ELISA was carried out according to the manufacturer's instructions. Briefly, undiluted serum samples from each participant were added to the appropriated wells of an anti-IL-29-coated plate in duplicate and incubated for 60 min at 37°C. After discarding the soluble and washing the wells, streptavidin-horseradish peroxidase was added to each well, incubated, washed, then substrate reagent, tetramethylbenzidine (Pishtazteb) was added and incubated for (10 min at 37°C) in the dark. The addition of H 2 SO 4 stopped the reaction, and the optical density was read at 450 nm using 630 nm as the reference wavelength. All the variables were shown as frequencies and percentages. To compare the continuous variables for data of different patient groups, Mann-Whitney test was used as appropriate. The frequencies of categorical variables were compared using the χ 2 and Fisher's exact test as appropriate. All statistical analyses and graphs were generated and plotted using GraphPad Prism version 9.00 software. The p < 0.05 was considered statistically significant. The clinical data of 26 severe patients, including 84.62% male and 15.38% female with a mean age of 66.38 ± 17.30 were evaluated. Furthermore, the second group included 24 nonsevere patients with a mean age of 52.92 ± 16.45 (75% were male and 25% were female). The most common symptoms of the illness in the recovered group did not show any significant differences in the recovered group in comparison with the patients of the death group. There were no significant differences between the two groups on clinical symptoms (p > 0.05). To determine the role of IL-29 in COVID-19 infection and its effect on the mortality of the patients, serum levels of IL-29 were examined in dead patients (before death) as well as recovered patients (Table 1 ). Using the Mann-Whitney test, the significant differences among the severe (deceased) group patients compared to recovered individuals have been found (p = 0.007) (Figure 1 ). The level of IL-29 cytokine was significantly higher in recovered (0.09217 ± 0.06037) compared to dead patients (0.05158 ± 0.03680). Further analysis of clinical characteristics, common initial symptoms, comorbidity, and laboratory findings of these two groups can be found in Table 1 . Since December 2019, SARS-CoV-2 has rapidly infected millions of people from all over the world (JHU data June 5, 2020; https:// coronavirus.jhu.edu/). In less than a quarter of cases that developed severe pneumonia, hospitalization, and oxygen therapy are needed. Also, admission to the intensive care unit is essential for patients T A B L E 1 Clinical characteristics, common initial symptoms, comorbidity, and laboratory findings of the admitted patients with coronavirus disease-19 However, the important point is how SARS-CoV-2 escapes from the immune system; not much information is available yet. The limited number of participants can be considered as a limiting factor of the study. Through our survey on the host cytokine effects on the COVID-19 complications, our data suggest the protective role of IL-29 in patients with COVID-19 and decreased levels of this cytokine could predict the severe condition in the COVID-19. Also, high levels of IL-29 might have a correlation with leukocyte, lymphocyte, and neutrophil count in the peripheral blood, which needs more investigation. To achieve better interpretation, evaluating the levels of other cytokines, especially T1IFNs, is helpful. All together higher profiles of IL-29 in patients' immune systems can be accompanied by a better prognosis. F I G U R E 1 The levels of interleukin-29 (IL-29) in COVID-19 patients (recovered and dead). There was a significant difference among the dead patients compared to recovered patients. The serum concentration of IL-29 was demonstrated as mean ± SD Drug targets for corona virus: a systematic review COVID-19: immunology and treatment options Immunology of COVID-19: current state of the science Insights into IL-29: emerging role in inflammatory autoimmune diseases The role of IL-29 in immunity and cancer Weak induction of interferon expression by SARS-CoV-2 supports clinical trials of interferon lambda to treat early COVID-19 Clinical characteristics of coronavirus disease 2019 and development of a prediction model for prolonged hospital length of stay Identification of risk factors for mortality associated with COVID-19 Interferon-λ-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells Interferon-λ is functionally an interferon but structurally related to the interleukin-10 family Interferon-λ mediates non-redundant front-line antiviral protection against influenza virus infection without compromising host fitness Interleukin-29 profiles in COVID-19 patients: survival is associated with IL-29 levels The authors declare no conflicts of interest. The corresponding author, Sanaz Mami had full access to all of the data in this study and takes complete responsibility for the integrity of the data and the accuracy of the data analysis. https://orcid.org/0000-0001-9369-8011